The fact that shares were issued on March 18th and
Post# of 5066
Posted On: 08/22/2014 3:34:05 PM
The fact that shares were issued on March 18th and we are now in August without any update whatsoever as to plan, ticker symbol, trading, plan for additional share offering etc. and the fact that previously stated milestone dates have come and gone without clear explanation of why and what the revised plan going forward is to me are growing signs not of an expert presentation to maximize value since non communication of serious timeline changes (such as ongoing 3 month+ "clarification" of major IND drug HemaXelerate I) do not inspire confidence, but breed suspicion and/or lack of confidence in major investors.
If Regen truly has either HemaXellerate I or dCellVax in a position to possibly receive FDA clinical trial approval within the next 1-3 months, communicating that openly would attract interest and possibly larger investors' attention.
But issuing PRs with time frames that don't come to fruition and then going for weeks in silence with only required financial reports communicated without associated PRs or company updates is a pattern that no longer breeds confidence in me that we are anywhere close to a major breakthrough.
Based on the past, here is what we can now expect:
Silence through August.
Late Sept or early Oct, a PR stating that Regen has an IND # for a filing of dCellVax, but no other concrete info other than standard: "This is a great step forward for the company".
December - Regen is in communication with the FDA regarding the questions they raised with the IND dCellVax filing submitted in August. "Regen considers this a normal step in the process of achieving FDA approval..."
Jan-Feb 2015 Regen has submitted modified IND for dCellVax and looks forward to working with FDA in the future to achieve full approval.
Between now and Jan 2015 - silence on HemaXellerate I as it fades into the sunset as a lost PR.
If it happens this way, our hope will have been in vain because it means we aren't any closer to anything.
If Regen truly has either HemaXellerate I or dCellVax in a position to possibly receive FDA clinical trial approval within the next 1-3 months, communicating that openly would attract interest and possibly larger investors' attention.
But issuing PRs with time frames that don't come to fruition and then going for weeks in silence with only required financial reports communicated without associated PRs or company updates is a pattern that no longer breeds confidence in me that we are anywhere close to a major breakthrough.
Based on the past, here is what we can now expect:
Silence through August.
Late Sept or early Oct, a PR stating that Regen has an IND # for a filing of dCellVax, but no other concrete info other than standard: "This is a great step forward for the company".
December - Regen is in communication with the FDA regarding the questions they raised with the IND dCellVax filing submitted in August. "Regen considers this a normal step in the process of achieving FDA approval..."
Jan-Feb 2015 Regen has submitted modified IND for dCellVax and looks forward to working with FDA in the future to achieve full approval.
Between now and Jan 2015 - silence on HemaXellerate I as it fades into the sunset as a lost PR.
If it happens this way, our hope will have been in vain because it means we aren't any closer to anything.
(0)
(0)